2. Academic Validation
  3. Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase

Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase

  • Bioorg Med Chem Lett. 2010 Apr 15;20(8):2634-8. doi: 10.1016/j.bmcl.2010.02.047.
John K Walker 1,  Shaun R Selness,  Rajesh V Devraj,  Michael E Hepperle,  Win Naing,  Huey Shieh,  Ravi Kurambail,  Syaulan Yang,  Daniel L Flynn,  Alan G Benson,  Dean M Messing,  Tom Dice,  Tina Kim,  R J Lindmark,  Joseph B Monahan,  Joseph Portanova
Affiliations

Affiliation

  • 1 Pfizer Global Research and Development, St. Louis, MO 63017, USA. jkwalker24@sbcglobal.net
PMID: 20227876 DOI: 10.1016/j.bmcl.2010.02.047
Abstract

Starting from an initial HTS screening lead, a novel series of C(5)-substituted diaryl pyrazoles were developed that showed potent inhibition of p38alpha kinase. Key to this outcome was the switch from a pyridyl to pyrimidine at the C(4)-position leading to analogs that were potent in human whole blood based cell assay as well as in a number of animal efficacy models for rheumatoid arthritis. Ultimately, we identified a clinical candidate from this substrate; SD-0006.

Figures
Products